Comparing three chemotherapy approaches for newly diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed AML confirmed by blood/bone marrow tests
- Age 18–65 years
- Good enough general health to tolerate intensive chemotherapy (ECOG score 0–2)
- Normal kidney and liver function (specific blood test results required)
- Strong heart function (ejection fraction >50%)
- Willing and able to sign consent and follow study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial tests a new combination of drugs (lisafotoclax, decitabine, and homoharringtonine) for people with AML who have already tried venetoclax and azacitidine and it didn’t work. The goal is to find a treatment that might work when the first therapy fails.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.